1
|
Wang B, Liu S, Liu X, Hu R, Qin A, Tang BZ. Aggregation-Induced Emission Materials that Aid in Pharmaceutical Research. Adv Healthc Mater 2021; 10:e2101067. [PMID: 34418328 DOI: 10.1002/adhm.202101067] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 07/19/2021] [Indexed: 12/14/2022]
Abstract
The in situ visualization of drugs can improve the understanding of their pharmacokinetics and mechanisms. Aggregation-induced emission (AIE) materials, which can aid in the visualization of drugs, are gradually being employed in pharmaceutical research due to their excellent fluorescence properties, good biocompatibility, and extremely high sensitivity. Herein, the progress of AIE materials in pharmaceutical research, including AIE carriers for drug delivery, AIE multifunctional prodrugs, and AIE compounds as bioactive reagents for theranostics is briefly described. Moreover, the opportunities and challenges of AIE materials in pharmaceutical research are discussed in depth. It is believed that versatile AIE materials hold great promise for the promotion of pharmacological research and can facilitate significant advancements in clinical fields.
Collapse
Affiliation(s)
- Bingnan Wang
- State Key Laboratory of Luminescent Materials and Devices Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates Center for Aggregation‐Induced Emission South China University of Technology Guangzhou 510640 China
| | - Shanshan Liu
- State Key Laboratory of Luminescent Materials and Devices Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates Center for Aggregation‐Induced Emission South China University of Technology Guangzhou 510640 China
| | - Xiaolin Liu
- Department of Chemistry Hong Kong Branch of Chinese National Engineering Research Centre for Tissue Restoration and Reconstruction Institute for Advanced Study and Department of Chemical and Biological Engineering The Hong Kong University of Science & Technology Clear Water Bay Kowloon Hong Kong 999077 China
| | - Rong Hu
- State Key Laboratory of Luminescent Materials and Devices Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates Center for Aggregation‐Induced Emission South China University of Technology Guangzhou 510640 China
| | - Anjun Qin
- State Key Laboratory of Luminescent Materials and Devices Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates Center for Aggregation‐Induced Emission South China University of Technology Guangzhou 510640 China
| | - Ben Zhong Tang
- State Key Laboratory of Luminescent Materials and Devices Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates Center for Aggregation‐Induced Emission South China University of Technology Guangzhou 510640 China
- Department of Chemistry Hong Kong Branch of Chinese National Engineering Research Centre for Tissue Restoration and Reconstruction Institute for Advanced Study and Department of Chemical and Biological Engineering The Hong Kong University of Science & Technology Clear Water Bay Kowloon Hong Kong 999077 China
- Shenzhen Institute of Molecular Aggregate Science and Engineering School of Science and Engineering The Chinese University of Hong Kong, Shenzhen 2001 Longxiang Boulevard, Longgang District Shenzhen City Guangdong 518172 China
| |
Collapse
|
2
|
Theodossiou TA, Wälchli S, Olsen CE, Skarpen E, Berg K. Deciphering the Nongenomic, Mitochondrial Toxicity of Tamoxifens As Determined by Cell Metabolism and Redox Activity. ACS Chem Biol 2016; 11:251-62. [PMID: 26569462 DOI: 10.1021/acschembio.5b00734] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Tamoxifen is not only considered a very potent chemotherapeutic adjuvant for estrogen receptor positive breast cancers but also a very good chemo-preventive drug. Recently, there has been a rising amount of evidence for a nongenomic cytotoxicity of tamoxifen, even in estrogen receptor negative cells, which has greatly confounded researchers. Clinically, the side effects of tamoxifen can be very serious, ranging from liver steatosis to cirrhosis, tumorigenesis, or onset of porphyrias. Herein, we deciphered the nongenomic, mitochondrial cytotoxicity of tamoxifen in estrogen receptor positive MCF7 versus triple-negative MDA-MB-231 cells, employing the mitochondrial complex III quinoloxidizing-center inhibitor myxothiazol. We showed a role for hydroxyl-radical-mediated lipid peroxidation, catalyzed by iron, stemming from the redox interactions of tamoxifen quinoid metabolites with complex III, resulting in Fenton-capable reduced quinones. The role of tamoxifen semiquinone species in mitochondrial toxicity was also shown together with evidence of mitochondrial DNA damage. Tamoxifen caused an overall metabolic (respiratory and glycolytic) rate decrease in the Pasteur type MCF cells, while in the Warburg type MDA-MB-231 cells the respiratory rate was not significantly affected and the glycolytiv rate was significantly boosted. The nongenomic cytotoxicity of tamoxifens was hence associated with the metabolic phenotype and redox activity of the cells, as in the present paradigm of Pasteur MCF7s versus Warburg MDA-MB-231 cells. Our present findings call for caution in the use of the drugs, especially as a chemopreventive and/or in cases of iron overload diseases.
Collapse
Affiliation(s)
- Theodossis Athanassios Theodossiou
- Department
of Radiation Biology, Institute for Cancer Research, The Radium Hospital, Oslo University Hospital, Montebello, Oslo 0379, Norway
| | - Sébastien Wälchli
- Department
of Cancer Immunology, Institute for Cancer Research, and Department
for Cellular Therapy, The Radium Hospital, Oslo University Hospital, Montebello, Oslo 0379, Norway
| | - Cathrine Elisabeth Olsen
- Department
of Radiation Biology, Institute for Cancer Research, The Radium Hospital, Oslo University Hospital, Montebello, Oslo 0379, Norway
| | - Ellen Skarpen
- Department
of Molecular Cell Biology, Institute for Cancer Research, The Radium
Hospital, Oslo University Hospital, Montebello, Oslo 0379, Norway
| | - Kristian Berg
- Department
of Radiation Biology, Institute for Cancer Research, The Radium Hospital, Oslo University Hospital, Montebello, Oslo 0379, Norway
| |
Collapse
|
3
|
Abstract
The anti-oestrogen tamoxifen, which is widely used in the treatment of breast cancer and is also approved for the prevention of this disease, causes an increased incidence of endometrial cancer in women. The ability of tamoxifen to induce endometrial tumours and the underlying carcinogenic mechanisms have been a subject of intense interest over the last approximately 20 years. They are central to the assessment of risks versus benefits for the drug, especially in a chemopreventive context. This review outlines the clinical justification for using tamoxifen as a chemopreventive agent and describes the genotoxic mechanisms considered responsible for tamoxifen-induced tumours in rat liver and how these might relate to women. In rat hepatic tissue, tamoxifen is metabolically activated via alpha-hydroxylation and sulphate conjugation to give a reactive species that binds to DNA predominantly at the N(2)-position of guanine, producing pro-mutagenic lesions. Whether tamoxifen-DNA adducts contribute similarly to the development of cancers in women depends on whether they can be formed in human tissues and the type of specific molecular and cellular responses they induce, if present. This review discusses the current data relating to these issues and highlights areas where further research is needed.
Collapse
Affiliation(s)
- Karen Brown
- Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE2 7LX, UK.
| |
Collapse
|
4
|
Brown K. Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. Expert Opin Drug Saf 2002; 1:253-67. [PMID: 12904141 DOI: 10.1517/14740338.1.3.253] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The anti-oestrogen tamoxifen, which is widely used as adjuvant therapy for breast cancer, is undergoing evaluation as a chemopreventive agent in women at increased risk of developing this disease. Recent results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 prevention trial show a 49% reduction in breast cancer incidence in healthy, high-risk women. However, tamoxifen treatment has the serious side effect of increasing the incidence of endometrial cancer in women and long-term administration of tamoxifen causes hepatic tumours in rats. These liver tumours are induced via a genotoxic mechanism, but the mechanisms responsible for endometrial cancer in women are not yet known and are a focus of much debate. This review describes the findings from the chemoprevention trials and problems associated with the use of tamoxifen in this setting. The mechanism of carcinogenesis in rat liver is explained in detail and compared to the situation in humans, with a view to assessing the risks associated with tamoxifen therapy and predicting whether other anti-oestrogens might be safer alternatives.
Collapse
Affiliation(s)
- Karen Brown
- Cancer Biomarkers and Prevention Group, The Biocentre, University of Leicester, University Road, Leicester, LE1 7RH, UK.
| |
Collapse
|
5
|
Curtis MG. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention. Drug Saf 2002; 24:1039-53. [PMID: 11735660 DOI: 10.2165/00002018-200124140-00003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
In general, the selective estrogen receptor modulators (SERMs) currently indicated for the treatment and prevention of breast cancer, i.e. tamoxifen and toremifene, are fairly well tolerated. However, tamoxifen has been shown to induce hepatocellular carcinomas in rats, but not in humans, and can increase the risk of endometrial cancer in humans by two to three times. Other potentially serious adverse effects which have been associated with tamoxifen and toremifene therapy include vasomotor symptoms, an increased risk of venous thromboembolic events, and an increased incidence of cataracts and ocular toxicity, fatty liver, and nonmalignant hepatic and uterine changes. In addition, long term tamoxifen use almost always results in resistance to the drug and, indeed, has actually been shown to promote tumour proliferation in human breast cancer cells. Both tamoxifen and toremifene display drug interactions with a variety of drug classes. The adverse events associated with these compounds have raised significant concerns regarding their widespread use for the treatment and prevention of breast cancer. In addition, because of the weakness and scarcity of the data on toremifene, any conclusions about its tolerability remain tentative until outcomes of ongoing clinical trials in the adjuvant setting are known. A third SERM, raloxifene, is the focus of several large randomised trials examining its efficacy in the prevention of breast cancer. At present, each potential adverse event needs to be weighed against potential benefits in the decision to undergo SERM treatment. An array of therapies is currently available for patients with breast cancer and women at increased risk of disease; the risk-to-benefit ratio for each agent should be carefully examined in determining the most advantageous regimen.
Collapse
Affiliation(s)
- M G Curtis
- Department of Obstetrics/Gynecology, University of Texas at Houston, Houston, Texas 77026, USA.
| |
Collapse
|
6
|
Zujewski J. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2002; 39:264-270. [PMID: 11921197 DOI: 10.1002/em.10054] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Tamoxifen has been shown to decrease the risk of invasive breast cancer by 49% and noninvasive breast cancer by 50%. Tamoxifen is also associated with a threefold increased risk of endometrial cancer. Raloxifene, a second-generation selective estrogen receptor modulator (SERM), has not been associated with endometrial cancer risk, and is currently under study in a large, multi-institutional, randomized Study of Tamoxifen and Raloxifene (STAR) for breast cancer prevention in postmenopausal women. A pilot trial of raloxifene in premenopausal women to assess the safety, tolerability, effects on bone mineral density, mammographic density, and other biological endpoints is ongoing. The retinoids have been shown to decrease mammary tumors in rodent carcinogenesis models. The Italian trial of fenretinide (4-HPR) in women with stage I breast cancer randomized women to fenretinide or no intervention. This study did not show an overall effect of decreasing the risk of contralateral breast cancer. However, a protective effect was suggested in premenopausal women. It has been suggested that this effect may be related to insulin-like growth factor 1 (IGF-1), which has been shown to be modulated by fenretinide in premenopausal but not postmenopausal women. Pilot studies of SERMs alone and in combination with retinoids or other agents provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women. These studies can provide information as to both the pathophysiology of carcinogenesis and the mechanism of action of chemopreventive agents, and help select agents and doses for testing in large randomized studies.
Collapse
Affiliation(s)
- JoAnne Zujewski
- Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
| |
Collapse
|
7
|
Moffat DF, Oien KA, Dickson J, Habeshaw T, McLellan DR. Hepatocellular carcinoma after long-term tamoxifen therapy. Ann Oncol 2000; 11:1195-6. [PMID: 11061618 DOI: 10.1023/a:1008354429921] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
We describe a case of hepatocellular carcinoma (HCC) after long term tamoxifen therapy in a 71-year-old woman. The patient was prescribed tamoxifen for 12 years following right mastectomy and axillary node clearance for breast carcinoma in 1985. In 1997, she complained of abdominal pain and fullness. An abdominal ultrasound scan showed lesions in the right lobe of liver which were thought to be metastases. However, a biopsy showed primary HCC. Studies in rats suggest that tamoxifen is involved in hepatic carcinogenesis but studies in humans have failed to show any increased risk. However, these studies followed up patients for less than five years. An increased risk of HCC may not become apparent until after a decade or more of tamoxifen therapy. In addition, HCC in tamoxifen treated patients may be under-reported since there may be reluctance to biopsy liver tumours which are assumed to be secondary carcinoma of the breast.
Collapse
Affiliation(s)
- D F Moffat
- University Department of Pathology, Western Infirmary, Glasgow, UK
| | | | | | | | | |
Collapse
|
8
|
Morrow M, Craig Jordan V, Takei H, Gradishar WJ, Pierce LJ. Current controversies in breast cancer management. Curr Probl Surg 1999. [DOI: 10.1016/s0011-3840(99)80804-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
9
|
Affiliation(s)
- C K Osborne
- Department of Medicine, University of Texas Health Science Center at San Antonio, 78284-7884, USA
| |
Collapse
|
10
|
Floren LC, Hebert MF, Venook AP, Jordan VC, Cisneros A, Somberg KA. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. Ann Oncol 1998; 9:1123-6. [PMID: 9834826 DOI: 10.1023/a:1008269025294] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Tamoxifen, a non-steroidal anti-estrogen, has been used successfully for a decade as post-operative adjuvant therapy for breast cancer. Tamoxifen is generally well tolerated with few side effects, especially at the typical dose of 10 mg twice daily. However, hepatic effects have been reported after tamoxifen administration and are usually found to be cholestatic in nature. Although previous reports concentrate on tamoxifen as a probable cause of drug-induced hepatotoxicity, very little attention has been focused on the use of tamoxifen in patients with pre-existing liver dysfunction and the possible need for dose adjustment. We present the case of a 48-year-old woman with an acute exacerbation of her pre-existing liver dysfunction and subsequent elevations of tamoxifen blood levels after approximately one year of tamoxifen therapy for adjuvant treatment of breast cancer. Tamoxifen dosing was adjusted based on serum levels.
Collapse
Affiliation(s)
- L C Floren
- Department of Biopharmaceutical Sciences, University of California, San Francisco, USA
| | | | | | | | | | | |
Collapse
|
11
|
|
12
|
Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 1997; 45:251-62. [PMID: 9386869 DOI: 10.1023/a:1005891506092] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Efficacy and safety of toremifene 60 and 240 mg daily (TOR60 and TOR240) are compared to 40 mg tamoxifen daily (TAM40) in postmenopausal women with advanced estrogen receptor (ER) positive or ER unknown breast cancer. The study is randomized and open label in three parallel groups. Primary efficacy variables are response rate and time to progression. WHO and ECOG criteria were used for measurable and nonmeasurable disease assessment, respectively. Safety was reported according to WHO criteria. Altogether 463 patients were randomized (157 to TOR60, 157 to TOR240, and 149 to TAM40). By data cut-off, after 20.5 months median follow-up time, over 70% of the patients had experienced disease progression. Response rates are 20.4%, 28.7%, and 20.8% in TOR60. TOR240, and TAM40, respectively. TOR60 and TAM40 show statistically equivalent efficacy and the difference between TOR240 and TAM40 is not significant (P = 0.112). Median times to progression are 4.9 (TOR60), 6.1 (TOR240), and 5.0 (TAM40) months and the corresponding hazard ratios (TAM:TOR) 1.015 and 1.124. Again, TOR60 and TAM40 are statistically equivalent and the difference between TOR240 and TAM40 is not significant (P = 0.374). All treatments were well tolerated. As a conclusion, TOR60 and TAM40 show equivalent clinical efficacy and tolerability. The higher dose of toremifene slightly but not statistically significantly improves response rate and time to progression. In postmenopausal women, toremifene 60 mg daily is an effective and safe treatment of advanced ER-positive or ER-unknown breast cancer.
Collapse
Affiliation(s)
- M Gershanovich
- N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia
| | | | | | | | | | | |
Collapse
|
13
|
Affiliation(s)
- V C Jordan
- Robert H. Lurie Cancer Center and Medical Oncology, Northwestern University Medical School, Chicago, IL 60611, USA
| | | |
Collapse
|
14
|
Abstract
The nonsteroidal antiestrogen tamoxifen is the most widely used anticancer drug. In women with breast cancer, adjuvant therapy with tamoxifen reduces relapse and improves overall survival. In advanced breast cancer, the response rate is more than 50% in hormonal dependent disease. In women treated with adjuvant tamoxifen the incidence of new primary breast cancers is decreased. This latter observation has led to the initiation of prevention trials. In 1989 the first report from a large prospective randomised trial showed a significant increase of endometrial carcinoma among women treated with adjuvant tamoxifen. This effect may be linked to the somewhat paradoxical estrogenic properties of tamoxifen. The endometrial effects should be considered in the long term use of tamoxifen, and should also be taken into account in the evaluation of the prevention trials. Animal data indicate that tamoxifen can induce tumours in other organ systems, for example the liver, but no increase in primary liver cancer has been reported from the randomised trials. In some of these trials an increase in other gastrointestinal cancers (e.g. colon and gastric carcinoma) has been observed. The mechanism behind this may be different from that of the endometrium. In animal systems, tamoxifen has shown to induce DNA damage, with formation of DNA adducts. The risk of secondary gastrointestinal cancer needs to be further evaluated. The adverse effects of tamoxifen have led to the development of new anti-estrogenic drugs and other estrogen reducing agents (e.g. aromatase inhibitors).
Collapse
Affiliation(s)
- N Wilking
- Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
| | | | | |
Collapse
|
15
|
Earl H, Gray R, Kerr D, Lee M. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom. Clin Oncol (R Coll Radiol) 1997; 9:141-3. [PMID: 9269542 DOI: 10.1016/s0936-6555(97)80067-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
16
|
Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996; 32A:1464-76. [PMID: 8911103 DOI: 10.1016/0959-8049(96)00184-0] [Citation(s) in RCA: 108] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Tamoxifen has been the endocrine treatment of choice for all stages of breast cancer for nearly a decade. Millions of women are currently receiving tamoxifen worldwide, while large-scale randomised trials have been launched aiming to investigate the drug's merit as a preventive agent. However, there are now concerns about tamoxifen's potential carcinogenicity. The goal of this review is to address these concerns, re-evaluate the available data from laboratory biological models and those from clinical reports and put the whole issue into perspective. Our focus is the association between tamoxifen and the increased frequency of endometrial tumours, while key issues, such as the role of duration of tamoxifen therapy, are also addressed. Finally, we discuss the various monitoring strategies for early detection of endometrial lesions and pertinent problems most likely to be encountered by clinicians taking care of patients who are receiving tamoxifen.
Collapse
Affiliation(s)
- V J Assikis
- Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago Illinois, USA
| | | | | | | |
Collapse
|
17
|
Abstract
A group of structurally related drugs representing diverse therapeutic classes share, among a number of pharmacological properties, enhancement of tumor growth in several rodent models of malignancy. One common action, the inhibition of histamine binding to and catalytic activity of cytochrome P450 monooxygenases, is highly correlated with potency to enhance tumor growth. Among members of this drug ensemble, the antiestrogen tamoxifen has been shown in controlled clinical studies to increase the incidence of uterine and gastrointestinal cancer and to accelerate the course of gastric cancer, and the tamoxifen analogue clomiphene has been linked to neuroblastoma and the tricyclic group of antidepressants to ovarian cancer. The determination of drug affinities for protein modulators of cell growth, proliferation, and transformation suggests a strategy for identifying at least some classes of chemicals that impart oncologic risks to humans.
Collapse
Affiliation(s)
- F S LaBella
- Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, Canada
| | | |
Collapse
|
18
|
Jiang SY, Shyu RY, Yeh MY, Jordan VC. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 1995; 23:712-9. [PMID: 8750171 DOI: 10.1016/0168-8278(95)80038-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND/AIMS Tamoxifen has previously been shown to prolong the survival of patients with advanced stages of hepatocellular carcinoma and it has been suggested that it inhibits the growth of hepatoma cells through an estrogen receptor-dependent mechanism. We have studied the effects of the synthetic estrogen, mestranol, and the antiestrogen, tamoxifen, on the growth regulation of hepatoma cells in vitro. METHODS Cells were maintained under fully estrogenized conditions and were deprived of estrogen shortly before conducting experiments. RESULTS In the human hepatoma cell line Hep 3B, tamoxifen inhibited cell growth in a concentration and time-dependent manner with effective concentrations ranging from 0.1 microM to 10 microM. Mestranol inhibited cell growth at a concentration of 10 microM and had an additive effect with tamoxifen on growth inhibition. Expression of estrogen receptors in hepatoma cells was not detected by enzyme immunoassay, Northern blot analysis or reporter gene expression assay. Furthermore, the introduction of estrogen receptors into Hep 3B cells did not alter the effect of tamoxifen and mestranol on cell growth. CONCLUSIONS This study suggests that tamoxifen inhibits the growth of Hep 3B hepatoma cells through an estrogen receptor-independent mechanism.
Collapse
Affiliation(s)
- S Y Jiang
- Graduate Institute of Medical Sciences, Tri-Service General Hospital, Taipei, Taiwan, Republic of China
| | | | | | | |
Collapse
|
19
|
Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994; 30A:1714-21. [PMID: 7833150 DOI: 10.1016/0959-8049(94)00349-a] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- V C Jordan
- Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois
| | | |
Collapse
|